Skip to main content
Explore URMC

menu

Study of the drug acalabrutinib and antibody rituximab in patients with leukemia or lymphoma

Research Question:
Is the combination of the drug acalabrutinib and antibody therapy, rituximab, safe and effective in patients who have previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)?

Basic Study Information

Purpose:
Despite an array of available therapies, chronic lymphocytic leukemia (CLL) remains an incurable disease. The development of an improved therapy would be a major contribution to the management of CLL and other B cell malignancies. The investigator proposes that the drug acalabrutinib will work better with an antibody treatment, rituximab, in the treatment of CLL.

Location: University of Rochester Medical Center
Study Reference #: ULYM18086

Lead Researcher (Principal Investigator)

Lead Researcher: Paul Barr

Study Contact Information

Study Coordinator: Andrew Bui
Phone: (585) 276-4405
Email: Andrew_Bui@URMC.Rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search